Faeth Therapeutics annual current ratio
2020
2021
2022
2023
2024
2025
Faeth Therapeutics Current Ratio Growth & History (FTH)
Faeth Therapeutics's current ratio was 5.06 for fiscal 2025.
View full Faeth Therapeutics company overviewFaeth Therapeutics annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 5.06 | −2.64 | −34.26% |
| 2024 | 2024-12-31 | 7.70 | −4.22 | −35.42% |
| 2023 | 2023-12-31 | 11.92 | −0.06 | −0.50% |
| 2022 | 2022-12-31 | 11.98 | −18.41 | −60.58% |
| 2021 | 2021-12-31 | 30.38 | 26.23 | +630.97% |
| 2020 | 2020-12-31 | 4.16 | — | — |
Faeth Therapeutics quarterly current ratio
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 19.69 | 12.06 | +157.91% |
| Q1 2026 | 2026-03-31 | 14.39 | 7.57 | +110.92% |
| Q4 2025 | 2025-12-31 | 5.06 | −2.64 | −34.26% |
| Q3 2025 | 2025-09-30 | 5.81 | −3.03 | −34.25% |
| Q2 2025 | 2025-06-30 | 7.64 | −3.26 | −29.95% |
| Q1 2025 | 2025-03-31 | 6.82 | −5.24 | −43.45% |
| Q4 2024 | 2024-12-31 | 7.70 | −4.22 | −35.42% |
| Q3 2024 | 2024-09-30 | 8.84 | −3.02 | −25.46% |
| Q2 2024 | 2024-06-30 | 10.90 | −4.23 | −27.97% |
| Q1 2024 | 2024-03-31 | 12.07 | −0.94 | −7.21% |
| Q4 2023 | 2023-12-31 | 11.92 | −0.06 | −0.50% |
| Q3 2023 | 2023-09-30 | 11.86 | −2.09 | −15.00% |
| Q2 2023 | 2023-06-30 | 15.13 | −8.33 | −35.50% |
| Q1 2023 | 2023-03-31 | 13.00 | −5.27 | −28.83% |
| Q4 2022 | 2022-12-31 | 11.98 | −18.41 | −60.58% |
| Q3 2022 | 2022-09-30 | 13.95 | −16.09 | −53.56% |
| Q2 2022 | 2022-06-30 | 23.46 | −18.75 | −44.42% |
| Q1 2022 | 2022-03-31 | 18.27 | −51.54 | −73.83% |
| Q4 2021 | 2021-12-31 | 30.38 | 26.23 | +630.97% |
| Q3 2021 | 2021-09-30 | 30.05 | — | — |
| Q2 2021 | 2021-06-30 | 42.22 | — | — |
| Q1 2021 | 2021-03-31 | 69.81 | — | — |
| Q4 2020 | 2020-12-31 | 4.16 | — | — |
Faeth Therapeutics current ratio trends
Over the last five fiscal years, Faeth Therapeutics's current ratio increased from 4.16 to 5.06, a change of 0.90. The latest reported quarter, Q2 2026, shows 19.69.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Faeth Therapeutics source filings ↗